Apalutamid for treatment of nonmetastatic castration-resistant prostste cancer – case study Case report

Main Article Content

Bożena Sikora-Kupis

Abstract

A special form of prostate cancer is non-metastatic castration-resistant prostate cancer. Patients with this form have rising prostate-specific antigen and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated with a significantly longer median metastasis-free survival. The featured description presents one case of man with non-metastatic castration- resistant prostate cancer who was treated with apalutamide.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Sikora-Kupis B. Apalutamid for treatment of nonmetastatic castration-resistant prostste cancer – case study. OncoReview [Internet]. 2023Mar.31 [cited 2024Jul.18];13(1(49):6-. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/2786
Section
SUPPORTIVE CARE IN ONCOLOGY

References

1. Yamada Y, Beltran H. The treatment landscape of metastatic prostate cancer. Cancer Lett. 2021; 519: 20-9. http://doi.org/10.1016/j.canlet.2021.06.010.
2. Cattrini C, Caffo O, De Giorgi U et al. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nm- CRPC): A Critical Review. Cancers (Basel). 2022; 14(7): 1792.
3. Mateo J, Fizazi K, Gillessen S et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2019; 75(2): 285-93.
4. Roumiguié M, Paoletti X, Neuzillet Y et al. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. Future Oncol. 2021; 17(14): 1811-23.
5. Mori K, Mostafaei H, Pradere B et al. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020; 25: 1892-900.